OCULAR THERAPEUTIX,INC. (NASDAQ:OCUL) Files An 8-K Other Events

ME Staff 8-k
-
0
OCULAR THERAPEUTIX,INC. (NASDAQ:OCUL) Files An 8-K Other Events

OCULAR THERAPEUTIX,INC. (NASDAQ:OCUL) Files An 8-K Other Events
Item 8.01 Other Events.

On October19, 2018, Ocular Therapeutix,Inc. issued a press release announcing the receipt of a warning letter related to ReSure®Sealant on October18, 2018 from the U.S. Food and Drug Administration. A copy of the press release is filed as Exhibit99.1 hereto and is incorporated herein by reference.

Item 8.01Financial Statements and Exhibits.

(d) Exhibits.

99.1

Press release issued by Ocular Therapeutix,Inc. on October19, 2018.


OCULAR THERAPEUTIX, INC Exhibit
EX-99.1 2 a18-36985_1ex99d1.htm EX-99.1 Exhibit 99.1   Ocular Therapeutix™ Receives FDA Warning Letter Related to ReSure® Sealant   BEDFORD,…
To view the full exhibit click here

About OCULAR THERAPEUTIX,INC. (NASDAQ:OCUL)

Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. Its hydrogel is a bioresorbable formulation of polyethylene glycol (PEG), which when constituted with water takes on a gelatinous consistency. The Company’s product pipeline includes marketed candidate ReSure Sealant and products under development, such as OTX-DP, OTX-TP, OTX-MP and anti-VEGF hydrogel depot. The Company’s lead product candidates are OTX-DP and OTX-TP. The OTX-DP product candidate incorporates the corticosteroid dexamethasone as an active pharmaceutical ingredient in its punctum plug. The OTX-TP product candidate incorporates the prostaglandin analog travoprost as an active pharmaceutical ingredient in its punctum plug.